About Sentonix
Sentonix is a Massachusetts biotech company developing precision treatments, including small-molecule drugs, for neurodegenerative diseases, and it is looking for ways to prevent those diseases. It was founded by a team of imaging scientists who had used biomarkers to guide drug development in neuroscience.
Its CEO, John Beaver, previously led global biomarker discovery and development at Biogen. In January 2026 Sentonix signed a global strategic collaboration with Mabwell, a drug maker listed in Shanghai, covering Parkinson's disease, Alzheimer's disease and other neurodegenerative diseases.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Aug 13, 2026 | Aug 20, 2026 | $12,704,719of $21.2M target | 17 | $747K | EquityRule 506(b) | Form D ↗ |
| Sep 23, 2024 | Oct 3, 2024amended May 12, 2025 | $6,499,590of $10.5M target | 15 | $433K | DebtRule 506(b) | Form D/A ↗1 earlier filing |
| Total, two offerings | $19,204,309 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Why Investors Backed Sentonix
Investors backed Sentonix for its plan to choose the right patients for brain-disease drugs before and during trials. Its founders are imaging scientists who used biomarkers to guide neuroscience drug development, and the company is developing small-molecule drugs for disorders such as Parkinson's and Alzheimer's. In January 2026 Mabwell, a Shanghai-listed drug maker, signed a global strategic agreement with it.
The problem it targets
Drug trials in Parkinson's, Alzheimer's and related diseases often fail; an industry report on the Mabwell deal put failure rates above 90%. Sentonix's answer is to use imaging and molecular markers to select patients and guide development, an approach its founders pioneered in neuroscience, according to Mabwell.
What the product does
Sentonix develops small-molecule drugs for neurodegenerative disorders, its investor Catalio Capital says, and it is also looking for ways to prevent these diseases. It has not named its drug candidates or published trial plans.
Progress so far
In January 2026 Mabwell (Shanghai) Bioscience signed a global strategic cooperation agreement with Sentonix to discover and develop drugs for Parkinson's disease, Alzheimer's disease and other neurodegenerative diseases. The two plan to work through joint development, new jointly formed companies and regional licenses, according to an industry report on the announcement.
Who backs it
Catalio Capital Management lists Sentonix in its portfolio as a seed-stage company. Kenan Turnacioglu, a former general partner at Catalio and a co-founder of PointState Capital, sits on the board.
We wrote this summary from public statements by Sentonix and its investors. It is not investment advice.
Sentonix in the News
Leadership Team
Executive officers and directors listed on Sentonix's Form D filed Aug 20, 2026.
